TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors
Gregory Chang(NYU Langone Health), David Polsky(New York University), Broderick C. Corless(Cornell University), Mahrukh M. Syeda(NYU Langone Health), Russell S. Berman(Cornell University), George Karlin‐Neumann(Bio-Rad (United States)), Shria Blake(SunEdison (United States)), Cindy Spittle(SunEdison (United States)), Jennifer Wiggins(New York University), Anna C. Pavlick(Cornell University), Farbod Darvishian(NYU Langone Health), Nathaniel H. Fleming(NYU Langone Health), Yongzhao Shao(New York University), Iman Osman(New York University), Jyothirmayee S. Tadepalli(NYU Langone Health), Richard L. Shapiro(NYU Langone Health)
Cited by 22
Related Papers
High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number
|Analytical Chemistry|2011|2.8k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
BRAF mutation predicts sensitivity to MEK inhibition
|Nature|2005|1.3k
Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment
|Nature Genetics|2022|527
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
|Journal of Clinical Oncology|2021|431